Clinical Trial Update: Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) [Phase 2]

View source ↗

Summary

Phase 2 trial results for TD1414 2% cream in impetigo and secondarily infected traumatic lesions report efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo
• Infected Traumatic Wounds

Drugs mentioned

• TD1414 2% Cream (TD1414)

Snippet

Sponsor: LEO Pharma | Conditions: Impetigo, Secondarily Infected Traumatic Lesions | Phase 2 | Status: COMPLETED | Results posted: 2018-07-23